Mogrify extends Series A financing to $46 million USD
The Company’s pipeline aims to address degenerative diseases of the eye, ear and pancreas via direct in vivo restoration of clinically valuable cell types
10-Oct-2023 -
Mogrify Limited, a biopharmaceutical company transforming the lives of patients through a novel class of in vivo reprogramming therapies, announced an additional $10 million USD closing of its Series A financing, bringing the total raised to $46 million USD in this round. The funding will support ...
diabetes
hearing loss
regenerative medicine
+1